Key Points• T SCM lymphocytes are preferentially generated from naive precursors in vivo early after haploidentical HSCT.• T SCM represent relevant novel players in the diversification of immunological memory after haploidentical HSCT.Memory stem T cells (T SCM ) have been proposed as key determinants of immunologic memory. However, their exact contribution to a mounting immune response, as well as the mechanisms and timing of their in vivo generation, are poorly understood. We longitudinally tracked T SCM dynamics in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT), thereby providing novel hints on the contribution of this subset to posttransplant immune reconstitution in humans. We found that donor-derived T SCM are highly enriched early after HSCT. We showed at the antigenspecific and clonal level that T SCM lymphocytes can differentiate directly from naive precursors infused within the graft and that the extent of T SCM generation might correlate with interleukin 7 serum levels. In vivo fate mapping through T-cell receptor sequencing allowed defining the in vivo differentiation landscapes of human naive T cells, supporting the notion that progenies of single naive cells embrace disparate fates in vivo and highlighting T SCM as relevant novel players in the diversification of immunological memory after allogeneic HSCT. (Blood. 2015;125(18):2865-2874
In allogeneic hematopoietic cell transplantation (allo-HCT), the immune recognition of host antigens by donor T lymphocytes leads to a beneficial graft-versus-leukemia (GvL) effect as well as to life-threatening graft-versus-host disease (GvHD). Genetic modification of T lymphocytes with a retroviral vector (RV) expressing the herpes simplex virus-thymidine kinase (TK) suicide gene confers selective sensitivity to the prodrug ganciclovir (GCV). In patients, the infusion of TK ؉ lymphocytes and the subsequent administration of GCV resulted in a time-wise modulation of antihost reactivity for a GvL effect, while controlling GvHD. Because activation required for genetic modification with RV may reduce antihost reactivity, we investigated the requirements for maximizing the potency of human TK ؉ lymphocytes. Whereas T-cell receptor triggering alone led to effector memory (EM)TK IntroductionAllogeneic hematopoietic cell transplantation (allo-HCT) is the curative option for many hematologic malignancies. Moreover, it is being investigated to treat solid tumors. In allo-HCT, the recognition of host antigens by donor T lymphocytes evokes a graft-versusleukemia (GvL) effect. 1 This is associated with the risk of graft-versus-host disease (GvHD). T-cell depletion prevents GvHD but increases the probability of leukemia relapse. Suicide gene therapy offers a pragmatic solution to the "T-cell dilemma" of allo-HCT. 2 A suicide gene codifies for a protein able to convert, at a cellular level, a nontoxic prodrug into a toxic product. Suicide gene modification of donor lymphocytes aims at exploiting allo-HCT for a GvL effect, while providing a selective "switch" to GvHD. 3 The thymidine kinase of herpes simplex virus (TK) is a cell cycledependent suicide gene, that is, it catalyzes the generation of triphosphate ganciclovir (GCV), which is toxic to proliferating cells. 4 In HLA-identical allo-HCT, delayed infusions of TK ϩ lymphocytes were effective against relapsing leukemia, lymphoma, multiple myeloma, and Epstein-Barr virus (EBV)-related lymphoproliferative disorders. 5 When administered at the time of transplantation, TK ϩ lymphocytes facilitated the engraftment of hematopoietic cells. 6,7 In patients developing GvHD, GCV administration eliminated circulating TK ϩ cells and controlled the disease. [5][6][7] Despite these encouraging results, dissemination of the TK technology has been limited by the difficulty in defining optimal conditions for cell manipulation. Current protocols for genetic modification of T lymphocytes with retroviral vectors (RVs) may reduce antigen responsiveness in vitro 8 and antihost reactivity in vivo. 9,10 Given the strict clinical association between GvL and GvHD, it may be postulated that the therapeutic efficacy of TK ϩ lymphocytes will be improved by protocols designed to maximize antihost reactivity in vivo.Genetic modification of T lymphocytes with RVs relies on cell proliferation and leads to a memory phenotype. 11,12 Different models have been proposed to describe mature T-cell differentia...
Islet survival in the early posttransplantation period is likely to be influenced by inflammatory events in and around islets. Twenty-seven human islet preparations were transplanted by 24 infusions into 14 patients with brittle type 1 diabetes under the Edmonton protocol. Patients were monitored for their coagulation [cross-linked fibrin degradation products (XDPs)] and liver function test [aspartate and alanine aminotransferase (AST and ALT)] as markers of early posttransplant complications, and these were correlated with in vitro islet number, purification, volume, monocyte-chemoattractant protein-1 (CCL2/MCP-1) and tissue factor (TF) islet release. Consistent with activation of coagulation pathways and hepatic damage, serum XDP values increased early after 11 infusions and transaminase after 13 of 24 infusions. TF and CCL2/MCP-1 were detected in supernatants of 21 and 22 islet preparations, respectively. Serum XDP peak values were correlated with TF/equivalent islets (EI) (r(2)=0.26, P = 0.001) and CCL2/MCP-1/EI (r(2) = 0.42; P < 0.001); serum transaminase areas under the curve in the first week posttransplantation were correlated with CCL2/MCP-1/EI (r(2) = 0.55; P < 0.001 for ALT and r(2) = 0.51; P = 0.001 for AST) and TF/EI (r(2) = 0.31; P = 0.002 for ALT, and r(2) = 0.36; P = 0.002 for AST). These data suggest that reducing the islet proinflammatory state may be a means to reduce the early posttransplant complications and perhaps improve islet engraftment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.